Why India's Novartis ruling is not patent Armageddon
The Supreme Court’s denial of Novartis’s Glivec patent has prompted dire warnings about patent protection in India, but practitioners say that the decision was just a straightforward application of the law
The patent in question involved a beta crystalline form of
Imatinib Mesylate, a molecule invented in the 1990s with a US
patent application from April 1994. The original molecule was
not patented in India because under Indian patent law,
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.